Literature DB >> 24852242

Progressive leukemic non-nodal mantle cell lymphoma associated with deletions of TP53, ATM, and/or 13q14.

Jennifer Chapman-Fredricks1, Jose Sandoval-Sus2, Francisco Vega1, Izidore S Lossos3.   

Abstract

Leukemic, non-nodal mantle cell lymphoma (MCL) is a relatively indolent disease characterized by asymptomatic leukemic presentation, non-nodal disease distribution, and slow disease progression, particularly in comparison to that of classic nodal MCL. We studied 3 cases of leukemic, non-nodal MCL in which TP53, ATM, and/or 13q14 deletions were identified. All three patients had disease progression leading to treatment requirements in two of the patients at 5 and 18 months after initial diagnosis. The third patient also clinically progressed 25 months after initial diagnosis but was lost to follow up despite recommendation for initiation of therapy. We present these cases as potential evidence that while leukemic non-nodal MCL is typically an indolent disease compared to classically defined mantle cell lymphoma, cytogenetic heterogeneity exists and cases with TP53, ATM, and/or 13q14 deletions may have a relatively aggressive clinical course.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ATM deletion; Leukemic mantle cell lymphoma; Non-nodal mantle cell lymphoma; TPp53 alteration

Mesh:

Substances:

Year:  2014        PMID: 24852242     DOI: 10.1016/j.anndiagpath.2014.03.006

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  6 in total

Review 1.  Mantle cell lymphoma--a spectrum from indolent to aggressive disease.

Authors:  Birgitta Sander; Leticia Quintanilla-Martinez; German Ott; Luc Xerri; Isinsu Kuzu; John K C Chan; Steven H Swerdlow; Elias Campo
Journal:  Virchows Arch       Date:  2015-08-23       Impact factor: 4.064

2.  Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14.

Authors:  Mathieu Gallo; Valère Cacheux; Laure Vincent; Caroline Bret; Ariane Tempier; Caroline Guittard; Alexandra Macé; Nicolas Leventoux; Valérie Costes; Vanessa Szablewski
Journal:  Virchows Arch       Date:  2016-09-07       Impact factor: 4.064

Review 3.  Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.

Authors:  Meri Tarockoff; Teresita Gonzalez; Stanislav Ivanov; Jose Sandoval-Sus
Journal:  Curr Oncol Rep       Date:  2022-05-31       Impact factor: 5.945

4.  CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course.

Authors:  Zhihong Hu; Yi Sun; Ellen J Schlette; Guilin Tang; Shaoying Li; Jie Xu; C Cameron Yin; Ken H Young; Keyur Pravinchandra Patel; Roberto N Miranda; Maitrayee Goswami; Michael Wang; Jeffrey L Jorgensen; L Jeffrey Medeiros; Sa A Wang
Journal:  Mod Pathol       Date:  2017-10-06       Impact factor: 7.842

5.  Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.

Authors:  Holly A Hill; Xinyue Qi; Preetesh Jain; Krystle Nomie; Yucai Wang; Shouhao Zhou; Michael L Wang
Journal:  Blood Adv       Date:  2020-07-14

Review 6.  Smoldering mantle cell lymphoma.

Authors:  Haige Ye; Aakash Desai; Dongfeng Zeng; Krystle Nomie; Jorge Romaguera; Makhdum Ahmed; Michael L Wang
Journal:  J Exp Clin Cancer Res       Date:  2017-12-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.